MK-1775 (ab147242)

Submit a review Submit a question

Overview

  • Product name

    MK-1775

  • Description

    Potent and selective small-molecule inhibitor of Wee1 kinase

  • Alternative names

    • AZD 1775
    • MK1775

  • Biological description

    Potent and selective small-molecule inhibitor of Wee1 kinase. Inhibits Wee1 (IC50 = 5.2 nM) in cell-free assays. Inhibits phosphorylation of CDC2 at Tyr15 (CDC2Y15), a direct substrate of Wee1 kinase in cell-based assays. Acts synergistically with gemcitabine in tumor cells. In a panel of 223 kinases, only 8 were inhibited >80% by 1μM MK-1775.

  • Purity

    > 98%

  • CAS Number

    955365-80-7

  • Chemical structure

    Chemical Structure

Properties

  • Chemical name

    1,2-Dihydro-1-[6-(1-hydroxy-1-methylethyl)-2-pyridinyl]-6-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-2-(2-propen-1-yl)-3H-pyrazolo [3,4-d]pyrimidin-3-one

  • Molecular weight

    500.60

  • Molecular formula

    C27H32N8O2

  • PubChem identifier

    24856436

  • Storage instructions

    Shipped at room temperature. Store at -20°C.

  • Solubility overview

    Soluble in DMSO to 200 mM

  • Handling

    Refer to SDS for further information.

    Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

  • SMILES

    CC(C)(C1=NC(=CC=C1)N2C3=NC(=NC=C3C(=O)N2CC=C)NC4=CC=C(C=C4)N5CCN(CC5)C)O

  • Source

    Synthetic

References

This product has been referenced in:

  • Barbosa RSS  et al. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines. Biochem Biophys Res Commun 519:597-604 (2019). Read more (PubMed: 31540690) »
  • Lindenblatt D  et al. Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma. BMC Cancer 18:922 (2018). Read more (PubMed: 30253737) »
  • Hirai H  et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 8:2992-3000 (2009). Read more (PubMed: 19887545) »

Publishing research using ab147242? Please let us know so that we can cite the reference in this datasheet.

Customer reviews and Q&As

Show All Reviews Q&A
Submit a review Submit a question

There are currently no Customer reviews or Questions for ab147242.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com